HC Wainwright & Co. Maintains Buy on Tarsus Pharmaceuticals, Raises Price Target to $106
Benzinga Newsdesk 1 hour ago
Analyst RatingsNewsPrice Target
HC Wainwright & Co. analyst Matthew Caufield maintains Tarsus Pharmaceuticals (NASDAQ:TARS) with a Buy and raises the price target from $88 to $106.
HC Wainwright & Co. analyst Matthew Caufield maintains Tarsus Pharmaceuticals (NASDAQ:TARS) with a Buy and raises the price target from $88 to $106.